Ânima (ANIM3) Q4 2024 earnings summary

Executive summary

• Achieved full integration of Laureate and Eu Médico Residente, unifying systems and teams, and entering a new sustainable growth phase with a leaner executive structure.

• Achieved 12 consecutive quarters of EBITDA margin expansion, with significant improvements in student experience, academic excellence, and brand strength, including OAB recommends Seal in Law.

• Inspirali received top Ministry of Education scores, expanded its medical education portfolio, and benefited from Mais Médicos III.

• Focused on operational efficiency, technology, and marketing, setting the stage for continued growth and improved student retention.

• Distributed R$246.8 million in dividends, reinforcing commitment to shareholder returns.

Financial highlights

• Consolidated net revenue grew 1.8% year-over-year to R$3,801.4 million in 2024.

• Adjusted EBITDA ex-IFRS16 rose 17.5% to R$1,084.9 million, with margin up 3.8 p.p. to 28.5%.

• Adjusted net income was R$187 million, reversing a prior year loss of over R$46 million.

• Leverage improved to 2.8x from 3.25x, with net debt at R$3,041.3 million.

• Cash position at year-end was R$1,252.0 million, up 27.2% from 2023.

Outlook and guidance

• Expectation to resume revenue growth in all segments in 2025, focusing on sustainable top-line growth and organic deleveraging.

• Confident in maintaining margin levels in digital and Inspirali segments, with continued investment in technology and efficiency.

• Capital budget for 2025 set at R$60.7 million, primarily for debt service and expansion investments.

• Inspirali positioned to benefit from Mais Médicos III, with ongoing commitment to operational efficiency and cash generation.